Posted by Michael Wonder on 27 Apr 2025
AbbVie submits biologics license application to US FDA for trenibotulinumtoxinE (TrenibotE) for the treatment of glabellar lines
24 April 2025 - Submission is supported by data from over 2,100 patients treated with TrenibotE throughout the clinical program.
AbbVie today announced submission of a biologics license application to the US FDA for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines.
